[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intellectual-disability\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intellectual-disability":693},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,40,0,25,[9,48,60,100,131,162,182,209,238,260,293,321,345,372,408,433,452,480,507,555,581,607,628,657,674],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100053233",false,"NCT05473429","Characterization of Nociception Phenotype in Individuals With Intellectual Disability","Characterization of the Nociception Phenotype in Individuals With Intellectual Disability","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\nFor All Participants\n\n* Provision of signed and dated informed consent form by participant or parent \u002F Legally Authorized Representative (LAR) of patient.\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Male or female, aged 8-30 years of age.\n* Agreement to avoid use of analgesics, NSAIDs, caffeine (24 hours before procedures), illicit substances and alcohol within 2 days prior to enrollment and during study participation.\n\nHealthy Adult Controls\n\n* IQ 85 OR General Adaptive Composite ABAS-3 score above 85\n* Must be fluent in the English Language.\n\nHealthy Children\n\n* OR ABAS-3 score above 85.\n* Must be fluent in the English Language.\n\nPatients\n\n-Diagnosis of Intellectual Disability.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\nAll participants\n\n* NIH employees or children of NIH employee who subordinate to an investigator in this study will be excluded. This will ensure that participation or refusal to participate cannot be perceived as having any beneficial or adverse effects on their employment. There will be no direct solicitation of employees or of employees' children by the employee's supervisor.\n* Allergic reactions to EEG water based gel.\n* History of concussions in individuals with an IQ\\>85.\n* Uncontrolled seizures.\n* Pregnancy (verbal confirmation). Pregnant women will be excluded as there is no data on the effects of nociception in pregnancy.\n* For healthy volunteers only - known history of neurological, psychiatric or pain disorders.\n* History of head injury resulting in prolonged loss of consciousness in individuals with an IQ\\>85.\n\nHealthy Children\n\n-Children who have been diagnosed with neurodevelopmental disorders or treated in early intervention programs.\n\nPatients\n\n-Subjects who are on opioids, NSAID, gabapentin, or pregabalin chronically.",true,"ALL","8 Years","30 Years",{"count":21,"type":22},215,"ESTIMATED","INTERVENTIONAL",[25],"NA","Background:\n\nPeople with intellectual disability (ID) often have physical disabilities as well. These physical problems can affect their bones, muscles, nerves, and gastrointestinal tracts. All of these issues can also cause pain. Yet little research has been done on pain in people with ID.\n\nObjective:\n\nTo compare brain responses to unpleasant stimuli in people with and without ID.\n\nEligibility:\n\nPeople aged 8 to 30 years diagnosed with an ID. Healthy volunteers without an ID are also needed.\n\nDesign:\n\nThe study requires only 1 visit of up to 4 hours. Participants with ID may come for up to 5 shorter visits instead.\n\nParticipants will take a test to measure their level of ID. They will have a physical exam.\n\nBoth groups will answer questions about pain and how their bodies react to it. They will answer questions about how they respond to things they see, feel, hear, smell, and taste. They will answer questions about their social behaviors. Caregivers may answer questions if the participant cannot.\n\nBoth groups will have a test to measure their brain activity. Participants will wear a special cap, like a swim cap, with sensors and wires. Sensors to examine the heart will be placed on the skin of their chest with stickers. An elastic band will be placed around the middle of their body to measure how fast they are breathing. Sensors to measure sweat will be placed on two fingers.\n\nParticipants will have heat, cold, brushing, and mild electrical stimuli to different parts of their body. Participants will rank how each stimulus feels using a scale with numbers or a scale with faces.",[28],"Intellectual Disability",[30,31,32,33,34],"EEG","fNIRS","Pain Thresholds","Brain Signals","Quantitative Sensory Testing","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":39},"2026-03-27",{"date":43,"type":22},"2026-10-06",{"name":45,"class":46},"National Institutes of Health Clinical Center (CC)","NIH",1,{"id":49,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":26,"conditions":52,"keywords":53,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":58,"leadSponsor":59,"locationsCount":47},"100475630",{"count":21,"type":22},[25],[28],[30,31,32,33,34],"2026-06-30",{"date":56,"type":39},"2026-07-01",{"date":41,"type":39},{"date":43,"type":22},{"name":45,"class":46},{"id":61,"slug":4,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":71,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":84,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100472474","NCT05432349","Rett Syndrome Registry","Rett Syndrome Real World Data Observational Registry","RSR","Inclusion Criteria:\n\n* Male or female with a pathologic loss of function alteration of MECP2\n\nExclusion Criteria:\n\n* Male or female with a gain of function alteration of MECP2, including those with MEPC2 duplication or triplication","0 Years","99 Years",{"count":70,"type":22},3000,"5 Years","OBSERVATIONAL","The Rett Syndrome Registry is a longitudinal observational study of individuals with MECP2 mutations and a diagnosis of Rett syndrome. Designed together with the IRSF Rett Syndrome Center of Excellence Network medical directors, this study collects data on the signs and symptoms of Rett syndrome as reported by the Rett syndrome experts and by the caregivers of individuals with Rett syndrome. This study will be used to develop consensus based guidelines for the care of your loved ones with Rett syndrome and to facilitate the development of better clinical trials and other aspects of the drug development path for Rett syndrome.",[75,76,77,78,28,79,80,81,82,83],"Rett Syndrome","Rett Syndrome, Atypical","Genetic Disease","Genetic Diseases, X-Linked","Neurobehavioral Manifestations","Neurologic Manifestations","Neurologic Disorder","Neurodevelopmental Disorders","Nervous System Diseases",[85,86,87,88,89],"Rett syndrome","MECP2","Neurodevelopmental disorder","Registry","Natural History Study","2026-06-26",{"date":54,"type":39},{"date":93,"type":39},"2022-08-02",{"date":95,"type":22},"2028-07",{"name":97,"class":98},"International Rett Syndrome Foundation","OTHER",19,{"id":101,"slug":4,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":110,"conditions":111,"keywords":117,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":47},"100517564","NCT06019182","MEHMO Natural History and Biomarkers","Investigations of Individuals With MEHMO Syndrome or eIF2-Pathway Related Conditions","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet the following criteria:\n\nBe \\>= 1-week of age if affected, or \\>=1-month of age if unaffected.\n\nFor Screening:\n\n1. Have a combination of signs\u002Fsymptoms suggestive of MEHMO syndrome,\n\n   AND\n\n   no or inconclusive molecular testing.\n\n   OR\n2. Be a relative of an individual with MEHMO syndrome\u002FeIF2-related condition and whose genetic may be informative for research.\n\nFor Main Study:\n\n1. Have a combination of signs\u002Fsymptoms suggestive of MEHMO syndrome,\n\n   AND\n\n   disease-associated variant(s) or variant(s) of uncertain significance in one of the eIF2-pathway related genes\n\n   OR\n2. Be a relative of an individual with MEHMO syndrome\u002FeIF2-related condition, AND a carrier of the pathogenic or likely pathogenic variant.\n\n   OR\n3. Be a non-affected, non-carrier family member of an individual with MEHMO syndrome or an eIF2-pathway related condition.\n\nEXCLUSION CRITERIA:\n\nAny individual who, in the opinion of the Investigators, is unable to comply with the protocol or have medical conditions that would potentially increase the risk of participation will be excluded from participation in this study.","1 Week","100 Years",{"count":109,"type":22},150,"This observational natural history study will follow individuals with MEHMO (Mental disability, Epileptic seizure, Hypopituitarism\u002FHypogenitalism, Microcephaly, Obesity) syndrome or an eIF2-pathway related disorder, who have symptoms such as intellectual delay, seizures, abnormal hormone and blood sugar levels, and decreased motor skills.\n\nNo current treatment for these conditions is available. A major impediment to the testing of potential therapeutic interventions is the lack of well-defined outcome measures. This protocol seeks to identify biochemical and clinical markers to monitor disease progression, and better understand the natural history of these conditions.\n\nAny person diagnosed with MEHMO syndrome or related conditions, who can travel to the NIH Clinical Center can participate in this study.\n\nThe study involves:\n\n* General health assessment and evaluation\n* Imaging studies\n* Laboratory tests\n* Collection of blood, urine, spinal fluid, skin biopsy.",[28,112,113,114,115,116],"Epilepsy","Hypogonadisms","Microcephaly","Nervous System Malformations","Obesity",[118,119,120,121],"MEHMO","X-linked MEHMO Syndrome","eIF2-Pathway Related Conditions","EIF2S3","2026-06-24",{"date":124,"type":39},"2026-06-25",{"date":126,"type":39},"2023-10-23",{"date":128,"type":22},"2053-09-01",{"name":130,"class":46},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",{"id":132,"slug":4,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":16,"sex":17,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":47},"100609919","NCT07220837","Online Learning Module to Advance Research Related to People With Disabilities","Randomized Control Trial (RCT) of Online Learning Module to Advance Research Related to People With Disabilities (D2\u002FR3)","D2\u002FR3","Inclusion Criteria:\n\n* Aged \\>=18\n* Conducts non-disability focused research (in the past 3 years)\n* Conducts (primarily) research with\u002Fon adults\n* Affirms their understanding that eligibility and data must pass quality assurance checks before compensation is disbursed\n\nExclusion Criteria:\n\n* Participant in Aim1\u002FAim2 of D2\u002FR3 study\n* Respondent fails to provide a valid US-based personal institutional email","18 Years",{"count":140,"type":22},200,[25],"This study will measure the effects of a brief one-time eLearning intervention on researcher Knowledge, Attitudes, and Perceptions (KAP) of including people with disabilities (PWDs) in biomedical \\& behavioral research. Researchers will be recruited from across the Einstein\u002FMontefiore network, and other medical centers with a focus on CTSAs.",[144,28,145],"Developmental Disability","Disability",[147,148,149,150,151,152],"Bias","Attitudes","Perceptions","Inclusion","Translational Science","Representation","2026-06-17",{"date":155,"type":39},"2026-06-22",{"date":157,"type":39},"2025-12-16",{"date":159,"type":22},"2026-08",{"name":161,"class":98},"Albert Einstein College of Medicine",{"id":163,"slug":4,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":71,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":47},"100597543","NCT07059858","Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities","Evaluation of Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities","Inclusion Criteria:\n\nFor Children with Intellectual Disabilities:\n\n* Aged between 5 and 12 years\n* Diagnosed with mild, moderate, or severe intellectual disability as documented by the ÇÖZGER (Child Special Needs Report)\n* Both the parent and the child agree to participate in the study\n\nFor Typically Developing Children\n\n* Aged between 5 and 12 years\n* Both the parent and the child agree to participate in the study\n\nExclusion Criteria:\n\nFor Children with Intellectual Disabilities:\n\n* Having a diagnosis of physical disability\n* Presence of a neurological anomaly affecting bladder and bowel functions\n* Parent does not consent to participate in the study\n* Having undergone trauma or surgery affecting bladder and bowel functions within the last 6 months\n* Diagnosis of a genetic disorder\n* Use of medications that may affect bladder and bowel functions\n\nFor Typically Developing Children\n\n* Presence of a neurological anomaly affecting bladder and bowel functions\n* Lack of parental consent to participate in the study\n* Having experienced trauma or undergone surgery affecting bladder and bowel functions within the past 6 months\n* Use of medications that may influence bladder and bowel functions","12 Years",{"count":170,"type":22},100,"Many neurodevelopmental, psychiatric, and medical disorders are commonly associated with intellectual disability. The presence of neurodevelopmental and psychiatric (NDP) comorbidities has been reported to negatively impact the clinical outcomes of bowel or bladder dysfunction.\n\nPediatric bladder and bowel dysfunction (BBD) is a common but underdiagnosed condition characterized by a spectrum of lower urinary tract symptoms and is often associated with constipation. Lower urinary tract symptoms include dysuria, urinary urgency, daytime incontinence, and enuresis, while bowel symptoms include constipation and encopresis. Most BBD cases are functional and not neurogenic in origin.\n\nIn children with special needs, all types of urinary incontinence are reported to occur more frequently compared to children without developmental or behavioral disabilities. Intellectual disability (IQ \\\u003C70) is also identified as a significant risk factor for urinary incontinence, with prevalence increasing as IQ decreases. In these children, lower urinary tract symptoms such as overactive bladder, dysfunctional voiding, and low fluid intake are also observed. Furthermore, according to support plans and medical records, 94% of individuals with intellectual and multiple disabilities experience constipation. Interestingly, lower levels of intellectual disability (profound and severe ID) have been associated with a lower prevalence of constipation.\n\nAlthough there are studies in the literature examining bladder and bowel functions separately in specific diagnostic groups with intellectual disability, the number of studies that assess bladder and bowel functions together in children with any form of intellectual disability is limited. Moreover, to our knowledge, there is no study in the literature that evaluates bladder and bowel functions along with child participation and parental quality of life in children with intellectual disability.\n\nBased on this gap in the literature, the aim of our study is to examine bladder and bowel functions, participation, and quality of life in children with intellectual disability",[28,173],"Healthy Subjects","2026-06-16",{"date":153,"type":39},{"date":177,"type":39},"2025-09-28",{"date":179,"type":22},"2026-12-02",{"name":181,"class":98},"Abant Izzet Baysal University",{"id":183,"slug":4,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":168,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":196,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":47},"100638999","NCT07624448","Regulating Together for Intellectual Disability and Autism: A Group Behavioral Therapy for for Emotion Dysregulation","Adapting a Group Intervention for Emotion Dysregulation in Autism and Intellectual Disability","RT-ID","Child Participant Inclusion Criteria:\n\n* Males, females, or non-binary youth between 8 and 12 years of age\n* Confirmed diagnosis of Autism Spectrum Disorder (ASD)\n* Confirmed diagnosis of Intellectual Disability\n* Fluent in spoken English.\n* Use of flexible phrase speech or greater\n* Meeting clinically significant emotion dysregulation criteria\n* Willing to participate in twice weekly 90-minute sessions\n* Family is willing to keep prescribed psychiatric medication and outside behavioral interventions stable\n* Parent, guardian, or legally authorized representative (LAR) must provide written permission on behalf of the participant\n\nChild Participant Exclusion Criteria:\n\n* Initiation of new psychosocial intervention within 30 days prior to first day of treatment\n* Presence of physical aggression in the child directed towards a peer outside the home (i.e., non-siblings) that resulted in injury within 30 days prior to screening. Other significant disruptive, aggressive, self-injurious, or sexually inappropriate behavior felt to be dangerous or overly disruptive to the group sessions will be reviewed by the study team on an individual basis.\n* Presence of comorbid major neuropsychiatric illness warranting other treatment approaches\n* Presence of any major sensory impairment that would limit participating in the material including blindness or uncorrected hearing loss\n\nCaregiver Inclusion Criteria:\n\n* Age ≥ 18 years\n* Lives and cares for their child with ASD+ID for \\> 50% of the year\n* Fluent in spoken English.\n* Willing to participate in twice weekly 90-minute sessions, including one virtual session weekly\n\nCaregiver Exclusion Criteria:\n\n-Presence of any major sensory impairment that would limit participating in the material including blindness or uncorrected hearing loss",{"count":190,"type":22},10,[25],"The goal of this study is to help children with autism and a co-occurring intellectual disability and their families learn practical strategies for managing issues like irritability, aggression, and other challenging behaviors. The main objective of this study is:\n\nTo adapt current Regulating Together materials to create an outpatient group program for emotion dysregulation in autism and co-occurring intellectual disability (ASD + ID) that will improve psychosocial outcomes for youth with ASD + ID.",[194,195,28],"Autism","Intellectual Disabilities With Other Behavioral Symptoms",[194,197,198,199],"intellectual disability","emotion dysregulation","aggression","2026-06-03",{"date":202,"type":39},"2026-06-05",{"date":204,"type":22},"2026-10",{"date":206,"type":22},"2027-12",{"name":208,"class":98},"Children's Mercy Hospital Kansas City",{"id":210,"slug":4,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":215,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":47},"100633842","NCT07531940","Escalating Doses of Memantine in Down Syndrome (MEDS-123)","Phase 1B Trial on Escalating Doses of Memantine in Down Syndrome","Inclusion Criteria:\n\n* Cytogenetically documented Trisomy 21 or Complete Unbalanced Translocation of Chromosome 21. Mosaic Trisomy 21 and partial translocations will be excluded from the study\n* No pregnancy by serum testing at screening. Females of child-bearing potential, sexually active must be practicing a reliable method of birth control. Urine pregnancy tests will be done at the 2 follow-up medical visits\n* Laboratory findings within normal limits or judged clinically insignificant at baseline\n* Vital signs within normal limits for age. Stable, medically treated hypotension will be allowed\n* ECG must demonstrate predominately normal sinus rhythm. Minor abnormalities documented as clinically insignificant will be allowed\n* Participants and their authorized representatives will provide written informed consent\n* Participants who have received any experimental drug for Down syndrome must undergo a washout\n* All participants must: Be in general good health as judged by the investigators; Be able to swallow oral medication; Have a reliable caregiver or family member who agrees to accompany participant to all visits, provide information about the participant as required by the protocol, and ensure compliance with the medication schedule; Be sufficiently proficient in English to reliably complete the study assessments\n* Age and gender matching participants without Down syndrome, must be: Males or females without Down syndrome aged-matching (within 3 years) participants with Down syndrome whom they are expected to serve as controls\n\nExclusion Criteria:\n\n* Participant weighing less than 40 kg\n* Current psychiatric or neurologic diagnosis other than Down syndrome (e.g., major depressive disorder, schizophrenia, bipolar disorder, autism, Alzheimer disease)\n* Current treatment with psychotropic drugs\n* Drug or alcohol abuse or dependence\n* Significant suicide risk or who would require treatment with electro-convulsive therapy or with psychotropic drugs during the study or who have received treatment with a depot neuroleptic drug within 6 months of entering the study.\n* Current or expected (within the next 6 months) hospitalization or residence in a skilled nursing facility (may reside in group homes or other residential settings with no skilled nursing)\n* Active or clinically significant conditions affecting absorption, distribution, or metabolism of study drug (e.g. inflammatory bowel disease or celiac disease)\n* Significant allergies to or other significant intolerance of memantine therapy, its ingredients, or with contraindications to memantine therapy as stated in the prescribing information\n* Participants who are expected to require general anesthetics during the course of the study\n* Presence or recent history of seizure disorder (\\\u003C 3 years).\n* Clinically significant and\u002For clinically unstable systemic disease. (Those with controlled hypothyroidism must be on a stable dose of medication for at least 3 months prior to screening and have normal serum T-4 and TSH at screening; and those with controlled diabetes mellitus must have an HbA1c of \\\u003C 8.0% and a random serum glucose value of \\\u003C 170 mg\u002Fdl)\n* Severe infections or a major surgical operation within 3 months prior to screening\n* History of persistent cognitive deficits immediately following head trauma.\n* Donation of blood or blood products less that 30 days prior to screening, while participating in the study, or four weeks after completion of the study\n* Inability to comply with the protocol or perform the outcomes measures due to significant hearing or visual impairment or other issues judged relevant by the investigators","15 Years","32 Years",{"count":7,"type":22},[219],"PHASE1","Down syndrome (DS) is typically caused by an extra chromosome 21 in the cell nucleus (trisomy 21, or T21). T21 is both the most common cause of genetically defined intellectual disability and the earliest documented cause of Alzheimer's disease (AD)-type pathology. Currently, all presymptomatic individuals with DS are classified as having 'Stage 0' DS-associated AD (DSAD). DSAD pathology evolves inexorably, with virtually all individuals with DS developing AD pathology by age 40, and approximately 50% meeting clinical dementia diagnosis criteria at 55 years of age. This study will test the hypothesis that the FDA-approved AD drug memantine, at higher-than-standard doses, may be effective as a cognitive enhancer in adolescents and young adults with DS. The primary goal of this phase 1b clinical trial will be the assessment of the safety and tolerability of three memantine doses in persons with DS. In addition, we will assess the effect of this drug on cognitive test scores and plasma biomarkers of AD in the study participants. Finally, we will also investigate steady-state plasma levels of memantine and the time course of memantine plasma levels after a single dose in the study participants (pharmacokinetics, or PK). The data generated through this phase 1b study will provide the essential safety, PK, and preliminary efficacy signals required to advance a phase 2 trial evaluating high-dose memantine as a first-in-class therapeutic strategy in DS.",[222,28],"Down Syndrome",[224,225,226,227],"Memantine","Episodic Memory","CVLT","Short-term memory","NOT_YET_RECRUITING","2026-05-05",{"date":231,"type":39},"2026-05-11",{"date":233,"type":22},"2026-06",{"date":235,"type":22},"2028-05",{"name":237,"class":98},"University Hospitals Cleveland Medical Center",{"id":239,"slug":4,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":16,"sex":17,"minAge":243,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100572773","NCT06737627","Development and Validation of the Observatory Battery of Common Eye Disorders for Adults With Intellectual Disability","Inclusion Criteria:\n\n1. Age 20 and above\n2. Primary caregivers for at least one adult with ID (have disability identification or (and) certification).\n\nExclusion Criteria:\n\n1. Unable to communicate in Mandarin or Taiwanese.(Primarycaregivers)\n2. Unable to cooperate with eye examination.(ID)","20 Years",{"count":245,"type":22},1400,"Background:\n\nAround 15% of the global population has some form of disability. Rights to obtain proper health care is an emphasis in the United Nationals Convention on the Right of People with Disability. Due to the importance of improving vision health for people with disabilities, studies on how to identify vision problems becomes extremely important in policy formulation for all countries. Among all types of disabilities, people with intellectual disability (ID) are among the ones where vision problems are the hardest to detect.\n\nCurrently, no caregiver assessable scales are available, as a result, adults with ID are at high risk of delayed diagnose for common ocular conditions. Objectives: This is a one-year project.\n\nThe objective of this study is two folds:\n\n1. To develop an item bank of ocular conditions of adults with ID;\n2. To develop a scale for caregivers to detect ocular conditions for adults with ID, and to validate the reliability, construct validity and responsiveness of the scale.",[28],[249],"Intellectual disability, Adults, Visual Scale, Caregiver","2026-04-21",{"date":252,"type":39},"2026-04-24",{"date":254,"type":39},"2024-04-09",{"date":256,"type":22},"2027-12-31",{"name":258,"class":98},"National Taiwan University Hospital",2,{"id":261,"slug":4,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":17,"minAge":138,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":23,"phases":269,"briefSummary":271,"conditions":272,"keywords":275,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":47},"100592728","NCT06997198","Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual\u002FDevelopmental Disabilities","Identification, Assessment, and Treatment of Tardive Dyskinesia With Deutetrabenazine in Adults With Intellectual\u002FDevelopmental Disabilities and Co-occurring Psychiatric and\u002For Behavioral Disorders","TD-AIDD","Participant Inclusion Criteria:\n\n* Diagnosis of IDD (IQ \\\u003C 70; social\u002Fadaptive dysfunction, onset \\\u003C age 22) as per DSM-5\n* Clinical diagnosis of Tardive Dyskinesia (TD) per DSM-5 for at least 3 months before study inclusion (presence of movement disorder for at least 3 months, in absence of previous formal diagnosis of TD).\n* Eligible to receive deutetrabenazine, according to current product labeling Stable doses of all psychotropic medications for minimum of three months before study inclusion\n* Willing to remain on stable doses of all psychotropics for 24 weeks of study. If female of childbearing age, practicing acceptable form of birth control throughout study duration.\n* Subject able to comply with scheduled visits and assessments\n* Consent of subject, or legally authorized representative to study protocol.\n\nCaregiver Inclusion Criteria:\n\n* Able to understand and answer questionnaires\n* Able to comply with scheduled visits\n* Ability to be primary Caregiver for 24 weeks of study\n\nParticipant Exclusion Criteria:\n\n* Previous treatment with a VMAT2 inhibitor (tetrabenazine, valbenazine, or deutetrabenazine).\n* Treatment with any investigational drug in the 30 days prior to study entry.\n* Currently taking a strong CYP2D6 inhibitor such as fluoxetine, paroxetine, quinidine, bupropion. Current treatment with strong anticholinergic agents, monoamine oxidase inhibitors, metoclopramide, dopamine agonists, L-DOPA, or stimulants within past 30 days, or botulinum toxin within the past 3 months.\n* Any unstable medical condition in the 60 days prior to study entry.\n* Pregnant or breast-feeding\n* Current or recent hepatic impairment\n* History of neuroleptic malignant syndrome\n* History of long QTc on electrocardiogram, bundle branch block (BBB), atrioventricular block, serious cardiac arrhythmia, or heart failure.\n\nQTc on EKG \\> 450 msec (Fredericia formula) on EKG within 3 months prior to study entry.\n\n* History of substance abuse or dependence in the 3 months prior to study entry.\n* Significant risk of suicide or dangerous aggression to others at time of or 3 months prior to study entry.\n* Inability to take study medications\n\nCaregiver Exclusion Criteria:\n\n* Unable to complete questionnaires\n* Unable to comply with scheduled visits\n* Will not be a primary Caregiver for the 24 weeks of the study","89 Years",{"count":7,"type":22},[270],"PHASE4","The primary goal of this study is to investigate the efficacy of deutetrabenazine treatment of TD in this previously untreated patient population. Compare movement disorder deutetrabenazine treatment response in persons with IDD to response seen in patients without IDD treated with deutetrabenazine in other treatment settings (per literature review). Compare global deutetrabenazine treatment response with validated instruments.\n\nIn addition, we plan to:\n\n* Assess the safety of deutetrabenazine in the treatment of TD in persons with IDD.\n* Assess change in Activities of Daily Living (ADLs) in persons with IDD and TD treated with deutetrabenazine, utilizing a validated ADL instrument.\n* Assess change in Quality of Life (QOL) in persons with IDD and TD treated with deutetrabenazine, utilizing a validated QOL instrument.\n* Assess caregiver burden with a validated caregiver burden instrument.\n\nIn this study, 25 participants with IDD and TD will undergo Deutetrabenazine treatment for 24 weeks. The participants will be seen for a total of 5 visits: at baseline, and at follow up visits at 3 weeks, 6 weeks, 12 weeks, and 24 weeks.\n\nThis study does not include a comparison group. Therefore, researchers will compare the response of the study participants to deutetrabenazine treatment with those from a previous reported work that resulted in the FDA approval of this medication. This will be an open-label, Phase 4 study.",[273,28,274],"Tardive Dyskinesia","Developmental Disabilities",[276,277,278,279,280,281,282,283,284],"movement disorders","antipsychotic medication adverse effects","Abnormal Involuntary Movement Scale","quality of life","adaptive behavior","caregiver burden","deutetrabenazine","selective vesicular monoamine transporter 2 inhibitor","VMAT2 inhibitor","2026-04-03",{"date":287,"type":39},"2026-04-09",{"date":289,"type":22},"2026-05-01",{"date":291,"type":22},"2027-10-01",{"name":237,"class":98},{"id":294,"slug":4,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":16,"sex":17,"minAge":299,"maxAge":300,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":317,"leadSponsor":319,"locationsCount":4},"100631760","NCT07504874","The Effect of Gardening Activities on the Quality of Life of Students With Mild Intellectual Disability","The Effect of Gardening Activities on the Quality of Life of Mildly Intellectually Disabled Secondary School Students: A Mixed-Method Study","Inclusion Criteria:\n\n* Students studying at a special education secondary school,\n* Who are open to communication and collaboration,\n* Who have no physical or mental disabilities that would prevent them from participating in gardening activities,\n* And whose parents have provided written informed consent for their participation will be included in the research.\n\nExclusion Criteria:\n\n* Students who do not attend the educational program regularly will be excluded from the research.","11 Years","14 Years",{"count":302,"type":22},30,[25],"This study will be conducted to determine the effect of gardening activities applied to mildly intellectually disabled secondary school students on their quality of life and to examine their views on these activities in depth.",[28,306],"Quality of Life",[308,309,310,311,312],"Intellectual disability","Gardening activities","Quality of life","Nursing","Mixed method","2026-04-02",{"date":315,"type":39},"2026-04-08",{"date":289,"type":22},{"date":318,"type":22},"2026-12-01",{"name":320,"class":98},"Ordu University",{"id":322,"slug":4,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":17,"minAge":328,"maxAge":329,"enrollmentInfo":330,"targetDuration":4,"studyType":23,"phases":331,"briefSummary":332,"conditions":333,"keywords":334,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":47},"100496457","NCT05744479","Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability","Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability: A Double-Blind Randomized Control Trial","METIDD","Inclusion Criteria:\n\n* Stable outpatients\n* Age 16-65 years\n* Diagnosed with an IDD\n* On maintenance treatment with an antipsychotic (stable dose for ≥3 months).\n* BMI must be ≥30 kg\u002Fm2, OR ≥27 kg\u002Fm2 with at least one weight-related comorbidity (treated or untreated) such as: hypertension, dyslipidaemia, obstructive sleep apnea, or impaired fasting glucose, OR \\>=25 for individuals who have gained \\> 5% body weight in association with AP use.\n* Females of child-bearing age must be on one of the following regular contraceptives:\n\n  1. Agree to abstain from sex for the duration of the trial or\n  2. A barrier method of a diaphragm with spermicide and\u002For Latex condom or\n  3. An oral contraceptive agent, implantable contraceptive or an injectable contraceptive for at least six months prior to entering the study and will continue its use throughout the study, or\n  4. An intrauterine device, or\n  5. Partner has had a vasectomy at least 3 months prior to study start\n\nExclusion Criteria:\n\n* Females who are nursing, currently pregnant, or have a positive pregnancy test\n* Clinical or laboratory evidence of uncompensated cardiovascular, endocrine, haematological, hepatic, renal, or pulmonary disease\n* Previous treatment and lack of efficacy or tolerability with metformin\n* History or diagnosis of Type 1 Diabetes (T1D) or Type 2 Diabetes (TD2) or fasting blood work, HbA1c \\> 6.5%\n* History of metabolic acidosis or lactic acidosis\n* Treatment with weight-lowering agents\n* Medications with significant renal impact\n* Major medical or surgical event in the preceding 3 months\n* Acute suicidal risk.\n* Moderate to severe substance use disorder, other than caffein or nicotine use disorder","16 Years","65 Years",{"count":170,"type":22},[270],"People with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease. While antipsychotics contribute to this problem, their use is necessary and appropriate in a significant subgroup of individuals with IDD. Exercise and diet interventions have limitations and may not be sufficient, requiring effective adjunctive pharmacological approaches to target obesity and related comorbidities in IDD. However, persons with IDD treated with antipsychotics are systematically excluded from clinical trials hindering development of evidence to help guide safe and effective treatment of these comorbidities. Moreover, evidence from other disorders cannot be extrapolated to IDD given inherent biological differences between disorders. This trial will address the identified gaps, which extend beyond cardiovascular morbidity and negatively impact psychosocial outcomes, in a hugely underserviced population.This is the the first RCT (randomized control trial) to examine the efficacy of metformin in overweight or obese adults with IDD who have experienced antipsychotic-induced weight gain. By generating efficacy data for a very accessible and scalable intervention, allows for guideline and implementation strategies to address a recalcitrant health problem.",[28,144,116],[28,144,116,335],"Metformin","2026-03-26",{"date":338,"type":39},"2026-03-31",{"date":340,"type":39},"2023-02-28",{"date":342,"type":22},"2027-03-01",{"name":344,"class":98},"Centre for Addiction and Mental Health",{"id":346,"slug":4,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":17,"minAge":138,"maxAge":351,"enrollmentInfo":352,"targetDuration":4,"studyType":23,"phases":354,"briefSummary":355,"conditions":356,"keywords":357,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":47},"100629547","NCT07476092","Evaluation of the Effect of Digital-based Games on the Visual and Cognitive Performance of Young Children With Intellectual Disabilities","Evaluation of the Effect of Digital-based Games on the Visual and Cognitive Performance of Young Children With Intellectual Disabilities: A Randomized Controlled Study","Inclusion Criteria:\n\n* Individuals aged 18-35 years\n* Diagnosed with mild or moderate intellectual disability\n* Receiving services from EÇADEM\n* Ability to participate in cognitive activities\n* Written consent from parents\u002Fguardians\n* No visual or hearing impairment\n* No severe motor coordination problems\n\nExclusion Criteria:\n\n* Severe intellectual disability\n* Visual or hearing impairment\n* Any medical condition preventing participation\n* Lack of participant or parental consent","35 Years",{"count":353,"type":22},60,[25],"This randomized controlled trial aims to evaluate the effect of digital intelligence games on visual and cognitive performance in young individuals with intellectual disabilities. Participants aged 18-35 years receiving services from EÇADEM in Istanbul will be randomly assigned to either an intervention group receiving digital intelligence game training using the MentalUP application or a control group receiving routine services. Visual memory and cognitive performance will be assessed using the Benton Visual Retention Test and the Standardized Mini Mental Test at baseline, 3 months, 6 months, and 12 months. The study will investigate the short- and long-term effects of digital cognitive training on visual and cognitive functioning.",[28],[28,358,359,360,361,362],"Cognitive Performance","Visual Memory","Digital Intelligence Games","Randomized Controlled Trial","MentalUP","2026-03-16",{"date":365,"type":39},"2026-03-18",{"date":367,"type":39},"2025-06-01",{"date":369,"type":22},"2026-06-01",{"name":371,"class":98},"Koç University",{"id":373,"slug":4,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":16,"sex":17,"minAge":138,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":23,"phases":381,"briefSummary":382,"conditions":383,"keywords":394,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":259},"100572968","NCT06740162","Physical Activity and Community EmPOWERment Project","A Stage 1 Pilot Test for Feasibility and Efficacy of a Multi-Level Intervention to Increase Physical Activity in Adults With Intellectual Disability: Physical Activity and Community EmPOWERment (PACE)","PACE","Inclusion criteria for adults with ID will include:\n\n* ages 18 and older with a prior clinical diagnosis of ID, confirmed by scores \\\u003C 70 and + 90% on the Leiter-3 International Performance Scales and\u002For an adaptive behavior measure using the Vineland Adaptive Behavior Scales,\n* Medical clearance to participate in moderate-to-vigorous physical activity as determined by the American College of Sports Medicine (ACSM) preparticipation algorithm,\n* Adult does not show clinically elevated symptoms of Alzheimer's Disease (AD)\u002F Alzheimer's Disease and Related Dementias (ADRD) as indicated by a score of \\\u003C 20 on the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities.\n* One caregiver\u002Fguardian is able and willing to participate.\n* must tolerate at least 8 hours of daily wear-time of Actigraph device during initial assessment period (4 of 7 days),\n* must average 20 minutes or less of moderate to vigorous physical activity (MVPA) minutes per day (140 MVPA minutes or less across 7-day period measured during the initial assessment period, and\n* must reside in North Carolina or Arkansas.\n\nExclusion Criteria for adults with ID:\n\n• Diagnosis of AD, dementia, or related disorders. Participants will not be excluded based on gender, race, or ethnicity. There will be no upper age limit due to the heterogeneity of onset of AD\u002FADRD in individuals with ID.\n\nInclusion criteria for coach will include:\n\n* access to the internet and a mobile device,\n* has weekly contact with the adult participant with ID,\n* can converse and read in English to comprehend intervention materials and website content, and\n* must reside in North Carolina or Arkansas\n\nInclusion criteria for caregiver will include:\n\n* ability to converse and read in English to comprehend and answer interview questions, (2) must care for an adult with ID who is willing to participate in the study,\n* must reside in North Carolina or Arkansas, and\n* must attend all study visits with adult with ID.",{"count":380,"type":22},376,[25],"Purpose: Conduct a wait-list randomized controlled trial (RCT) of an inclusive physical activity program called PACE for adults with intellectual disability (ID) who are not yet showing signs of Alzheimer's Disease (AD)\u002Fage-related dementias (ARD).\n\nParticipants: Participants include 120 adults with ID, their caregivers, and their coaches (up to 360 individual participants, grouped as triads), recruited through the University of North Carolina at Chapel Hill and the University of Arkansas. Participants also include 16 exercise professionals.\n\nProcedures (methods): Each cohort will include 20 triads who are randomly assigned to the PACE program or the waitlist control group.",[28,82,384,222,385,386,387,388,389,390,391,392,393],"Autism Spectrum Disorder","Fragile X Syndrome","Cri-du-Chat Syndrome","De Lange Syndrome","Mental Retardation, X-Linked","Prader-Willi Syndrome","Rubinstein-Taybi Syndrome","Trisomy 13 Syndrome","WAGR Syndrome","Williams Syndrome",[395,197,396,397,398],"physical activity","age-associated memory impairment","aging","Alzheimer Disease prevention","2026-02-19",{"date":401,"type":39},"2026-02-23",{"date":403,"type":39},"2025-01-10",{"date":405,"type":22},"2028-06",{"name":407,"class":98},"University of North Carolina, Chapel Hill",{"id":409,"slug":4,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":416,"conditions":417,"keywords":420,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":47},"100623767","NCT07400913","Implementation of Long-read Sequencing for the Diagnosis of Rare Diseases.","Implementation of Long-read Sequencing for Epimutation Detection in the Diagnosis of Rare Diseases.","LongEpi","Inclusion Criteria:\n\n* Adult patients,adults under guardianship, or minors with autorisation from their legal representative, for whom extracted DNA or a tube of frozen blood is available in the molecular genetics laboratory.\n* Patients investigated for either :\n\n  * a syndromic intellectual development disorder (IDD) defined by:\n* age :\n\n  * Between 0 and 5 years with strict criteria: severe developmental delay in terms of motor skills, language and\u002For sociability OR\n  * ≥ 6 years: patients with IDD, regardless of severity (but with IDD proven by ad hoc neuropsychological tests)\n* association with minor morphological criteria and\u002For organ malformations.\n\n  * albinism defined by the presence of two of the following clinical signs: foveal hypoplasia, retinal hypopigmentation, iris transillumination, crossed asymmetry, nystagmus, skin\u002Fhair hypopigmentation (suggested diagnostic criteria proposed by Kruitj et al. (PMID: 30098354)).\n* Patients for whom genetic analyses (panel, exome, genome) are either :\n\n  * inconclusive (no pathogenic or probably pathogenic variant).\n  * A single heterozygous pathogenic or probably pathogenic variant identified in a gene associated with an autosomal recessive disease compatible with the phenotype.\n\nExclusion Criteria:\n\n* Refusal to participate in research protocols expressed at the time of written consent for genetic analysis as part of medical care.\n* Opposition expressed following receipt of information note.",{"count":109,"type":22},"Following on from the third national plan for rare diseases (PNMR3), the main objectives of the PNMR4 are to reduce diagnostic uncertainty and dead ends and to strengthen translational research to promote diagnosis and the development of new treatments in the field of rare diseases.\n\nTo this end, the French Genomic Medicine Plan 2025 (PFMG2025) is organizing the rollout of whole genome sequencing (WGS) for diagnostic purposes.\n\nThis technological milestone, covering regions outside the coding regions, has recently enabled the identification of variations in the RNU4-2 gene as a major cause of Intellectual Developmental Disorder (IDD), accounting for approximately 0.4% of cases. RNU4-2 is a gene encoding a small nuclear RNA (snRNA), which is not translated into protein, and whose variations are not accessible to exome sequencing techniques.\n\nHowever, based on current knowledge, these techniques are based on short-read sequencing technology and can diagnose up to 50% of patients. It is therefore necessary to develop new techniques to detect variations not identified by these techniques.\n\nIn this context, the development of third-generation sequencing, particularly using Nanopore technology, now makes it possible to combine genomic and post-genomic approaches through long-read whole genome sequencing coupled with the detection of methylated cytosines on native DNA.\n\nThis new approach therefore enables the simultaneous detection of point or structural genomic variants, methylation abnormalities, and haplotype reconstruction. Numerous studies have shown that this strategy improves the diagnosis rate of rare diseases and could become a first-line genetic test.\n\nDNA methylation is an epigenetic modification that does not cause changes in the genomic sequence but regulates the transcription (RNA synthesis) of genes and therefore their expression. Methylation studies are performed either to establish an episignature or to search for methylation abnormalities. An episignature is the result of a variation in a gene known to regulate methylation marks.\n\nMethylation abnormalities are already known and sought after in targeted analysis for certain diseases such as Prader-Willi\u002FAngelman syndromes and Beckwith-Wiedemann\u002FSilver-Russell syndromes. The contribution of methylation analysis to the diagnosis of other diseases has recently been demonstrated. For example, in methylmalonic aciduria and homocystinuria type cblC associated with the autosomal recessive gene MMACHC, promoter methylation analysis revealed hypermethylation linked to the presence of an intronic variant of the PRDX1 gene. This intronic variant leads to the synthesis of an aberrant antisense RNA overlapping the promoter of the MMACHC gene, causing its hypermethylation. In 2024, combined whole-genome and methylation analysis in patients with porokeratosis led to the discovery of the FDFT1 gene. In general, the study of methylation profiles has shown its value in reducing diagnostic uncertainty in patients with rare diseases who have not been diagnosed after genome analysis.\n\nThe search for methylation abnormalities (or epimutation) at the pan-genomic level in the context of molecular diagnosis of rare diseases remains largely inaccessible and poorly described in the literature. The techniques routinely used for their detection are most often based on bisulfite treatment and PCR amplification. The disadvantages of bisulfite treatment are that it degrades DNA, preventing long-read applications, that it does not distinguish between 5mC and 5hmC methylation, and that failure to treat unmethylated cytosines can lead to false positives . In addition, phase determination with a genomic variant identified in short reads requires complementary techniques such as SNP arrays.\n\nThis approach therefore appears to be a major technological advance in the fight against diagnostic uncertainty in rare diseases and is part of the move towards precision medicine for patients.\n\nAs part of our Reference Center for Developmental Anomalies and Malformation Syndromes of Southwest Occitanie Réunion (CRMR ADSOOR) at Bordeaux University Hospital, we have developed clinical and molecular expertise, particularly in the field of developmental anomalies with intellectual development disorders (particularly chromatinopathies and Rubinstein Taybi syndrome and albinism.\n\nIn 2024, 2,300 consultations were carried out at the CRMR. In addition, 243 and 228 genome or exome analyses were interpreted in our molecular biology laboratory for albinism and intellectual development disorder and malformation syndrome, respectively.\n\nOur expertise in these two areas therefore represents the best starting point for the development of this pilot project using this innovative approach at Bordeaux University Hospital.",[418,419,28],"Rare Diseases","Albinism",[421,422,423],"Rare diseases","Long-read sequencing","Epimutation","2026-02-03",{"date":426,"type":39},"2026-02-10",{"date":428,"type":22},"2026-02",{"date":430,"type":22},"2028-02",{"name":432,"class":98},"University Hospital, Bordeaux",{"id":434,"slug":4,"hasResults":11,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":17,"minAge":138,"maxAge":439,"enrollmentInfo":440,"targetDuration":4,"studyType":23,"phases":441,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":450,"locationsCount":259},"100579820","NCT06829264","Testing an Evidence-Based Supported Employment Model in Autistic Young Adults","A Pilot Trial of the Individualized Placement and Support Model in Autistic Adults in the Community","Inclusion Criteria: California supported employment agency clients meeting the following criteria:\n\n* Community diagnosis of autism spectrum disorder, demonstrated by a letter from a healthcare provider, psychologist, other mental health professional, Regional Center representative, or school psychologist.\n* Aged 18-40 years.\n* Minimum 4th-grade reading level (approximately mild ID).\n* Not currently employed but seeking employment.\n\nExclusion Criteria:\n\n\\- Not interested in employment.","40 Years",{"count":353,"type":22},[25],"This study aims to enhance employment outcomes for young adults with autism and intellectual and developmental disabilities (IDD) through the implementation of an evidence-based supported employment model known as Individual Placement and Support for Autism (IPS-AUT). The study will evaluate the feasibility, acceptability, and effectiveness of IPS-AUT in promoting Competitive Integrated Employment (CIE). The trial will involve partnerships with supported employment agencies, training providers in IPS-AUT, and assessing employment outcomes and implementation factors. The ultimate goal is to create a scalable, evidence-based employment support model for individuals with autism.",[384,28],"2026-01-26",{"date":446,"type":39},"2026-01-28",{"date":448,"type":39},"2025-08-01",{"date":256,"type":22},{"name":451,"class":98},"University of California, Davis",{"id":453,"slug":4,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":11,"sex":17,"minAge":458,"maxAge":459,"enrollmentInfo":460,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":467,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":259},"100614357","NCT07278544","Harnessing Communication Preferences","Harnessing Communication Preferences to Enhance Its Persistence and Mitigate Relapse of Challenging Behavior","Inclusion Criteria:\n\n* 2 years old and older.\n* Diagnosis of intellectual or developmental disability.\n* Referred for assessment and treatment of challenging behavior.\n\nExclusion Criteria:\n\n* Challenging behavior does not occur within the context of structured assessment, eliminating the ability to identify its operant function, or the behavior is deemed too dangerous to safely observe during assessment.\n* Communicate functionally using vocal\u002Fverbal communication.\n* Can only identify one proficient AAC strategy.","2 Years","90 Years",{"count":353,"type":22},[25],"The goal of this clinical trial is to evaluate how preference for communication approach (e.g., using a touch talker versus picture cards) impacts treatment maintenance in the context of treatment to reduce challenging behavior exhibited by individuals with intellectual and\u002For developmental disabilities. As well, the clinical trial will evaluate how this preference impacts treatment relapse when care providers implement intervention and will identify potential demographic variables (e.g., age and symptom severity) that affect outcomes.\n\nThe main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\nPreferred communication strategies will persist to a greater extent when intervention is disrupted, relative to less preferred communication strategies.\n\nCommunication modality preference will increase persistence for individuals with lower pre-experimental symptom severity scores and higher pre-experimental communication functioning scores. We predict demographic characteristics and developmental level will not impact intervention outcomes.\n\nTwo groups will be compared. Group 1 will receive initial intervention using a preferred communication strategy. Group 2 will receive initial intervention using a non preferred, but effective, communication strategy. Intervention type will then be reversed. Researchers will compare preferred and non preferred interventions on continued expression of the communication strategy when intervention is challenged.\n\nParticipants will exhibit alternative appropriate communicative behavior as a means of replacing\u002Freducing challenging behavior. This will take place using (a) preferred communication strategies and (b) non preferred communication strategies. Following successful intervention with each type of communication, intervention will be challenged and continued use of the communication strategy will be measured.",[28,384,464,465,466],"Self-Injurious Behavior","Communication Disabilities","Communication, Nonverbal",[468,469,470],"Functional communication training","Treatment maintenance","Behavioral relapse","2025-12-03",{"date":473,"type":39},"2025-12-12",{"date":475,"type":39},"2025-08-15",{"date":477,"type":22},"2031-03-31",{"name":479,"class":98},"Joel E. Ringdahl",{"id":481,"slug":4,"hasResults":11,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":485,"eligibilityCriteria":486,"healthyVolunteers":11,"sex":17,"minAge":168,"maxAge":138,"enrollmentInfo":487,"targetDuration":4,"studyType":23,"phases":489,"briefSummary":490,"conditions":491,"keywords":493,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":47},"100611790","NCT07245160","A Cognitive Behavioral Therapy Approach to Addressing Anxiety in Children With ASD and Intellectual Disability","Feasibility Study of Addressing Anxiety in Children With ASD and Intellectual Disability Through the Facing Your Fears Program","FYF","Inclusion Criteria:\n\n1. Children between the ages of 12-18 years\n2. Confirmed diagnosis of ASD that meets DSM-V criteria\n3. ADOS scores consistent with an ASD diagnosis\n4. WASI scores equivalent to 50-70\n5. CBCL with T score \\>\u002F= 70 for the anxiety subscale\n6. MASC-2\u002FSCARED score with T-scores reflecting clinically significant anxiety\n7. Not part of another interventional study or clinical trial\n8. Stable non-pharmacological therapies for at least 12 weeks\n9. Stable pharmacological therapies for at least 8 weeks\n10. Will not start new treatment for anxiety, medication or intervention, within the study 12 week study period\n11. Consistent parent partner per child throughout the duration of the study\n\nExclusion Criteria:\n\n1. Individuals with history of significant suicidal ideations or attempts\n2. Individuals involved in a concurrent interventional study",{"count":488,"type":22},24,[25],"Anxiety can be a debilitating and common concomitant diagnosis in autism spectrum disorders (ASD). Dependent on age and subtype of anxiety, the prevalence of anxiety in individuals with autism ranges between 1.7-84%. Meanwhile, the prevalence rate of intellectual disability (ID) in individuals with ASD ranges between 50-80% based on previous studies. There is an even greater risk of anxiety, ranging between 13.6- 43%, in individuals with ASD and ID. Despite the high prevalence of anxiety within this population, there are limited studies exploring assessments and treatments geared towards addressing anxiety in autism and intellectual disabilities. Previous studies have been limited to children who are identified as high functioning, or identified as low functioning without a concomitant diagnosis of ID. Given this, the present study focuses on the population of individuals with ASD and ID by exploring the feasibility of a CBT intervention designed for individuals with high-functioning autism\n\nThis pilot study aims at addressing and treating anxiety in children with ASD and intellectual disability through the Facing Your Fears (FYF) intervention. Facing Your Fears is a cognitive behavioral therapy (CBT) program specifically designed to address anxiety symptoms in children with autism. Research exploring the effectiveness of the FYF intervention within the population of individuals with ASD and ID is limited. This study aims at evaluating the feasibility of the Facing Your Fears program to address anxiety in children with ASD and ID, while evaluating the effectiveness of this intervention in larger group settings. The duration of the study will run over two 12-week cycles with study assessments conducted in-person, once a week. The study will involve 5-6 parent-child dyads to make up 10-12 participants per cycle. The child participants must be between the ages of 12-18 years old and have a confirmed diagnosis of ASD that meets DSM-V criteria. The study will commence with a month of recruitment, and a month allotted for collating data and assessments, before and after each 12-week intervention cycle. Evaluations will take place at screening, every study visit, and post intervention. Alongside the study evaluations, weekly sessions will involve didactic and practice sessions, with the last 30 minutes reserved for parent training. The sessions focus on the use and generalization of the taught strategies to address anxious symptoms, and exposure sessions outside of the weekly sessions. At the end of the 12-week cycle, the assessments related to the study outcomes will be administered again to allow investigators to compare and analyze pre- and post-intervention scores.",[492,28],"Autism Spectrum Disorder (ASD)",[494,495,496,497,197],"autism spectrum disorder","ASD","anxiety","cognitive behavioral therapy","2025-11-20",{"date":500,"type":39},"2025-11-24",{"date":502,"type":22},"2025-12-01",{"date":504,"type":22},"2026-12-31",{"name":506,"class":98},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":508,"slug":4,"hasResults":11,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":513,"targetDuration":71,"studyType":72,"phases":4,"briefSummary":515,"conditions":516,"keywords":521,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":47},"100323523","NCT03492060","Longitudinal Study of Neurogenetic Disorders","Neurogenetic Disorders: A Longitudinal Study on Natural History and Intervention Strategies","Inclusion Criteria:\n\n* Individuals must have had whole genome\u002Fexome sequencing and have a confirmed variant in any gene.\n\nExclusion Criteria:\n\n* Subjects who cannot provide genetic confirmation of a predicted deleterious variant in any gene.",{"count":514,"type":22},1000,"The purpose of this study is to analyze patterns in individuals with hnRNP (and other) genetic variants, including their neurological comorbidities, other medical problems and any treatment. The investigators will maintain an ongoing database of medical data that is otherwise being collected for routine medical care. The investigators will also collect data prospectively in the form of questionnaires, neuropsychological assessments, motor assessments, and electroencephalography to examine the landscape of deleterious variants in these genes.",[82,28,517,384,518,519,520],"Developmental Delay","Seizures","Hypertonia, Muscle","Hypotonia",[522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543,544,545],"Gene Variant","HNRNPA1","HNRNPA2","HNRNPB1","HNRNPC1","HNRNPC2","HNRNPD","HNRNPE1","HNRNPE2","HNRNPE3","HNRNPE4","HNRNPG","HNRNPH1","HNRNPH2","HNRNPI","HNRNPK","HNRNPL","HNRNPM","HNRNPP","HNRNPQ1","HNRNPQ2","HNRNPQ3","HNRNPR","HNRNPU","2025-10-24",{"date":548,"type":39},"2025-10-27",{"date":550,"type":39},"2018-06-13",{"date":552,"type":22},"2030-12",{"name":554,"class":98},"Columbia University",{"id":556,"slug":4,"hasResults":11,"nctId":557,"briefTitle":558,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":11,"sex":17,"minAge":138,"maxAge":351,"enrollmentInfo":561,"targetDuration":4,"studyType":23,"phases":563,"briefSummary":564,"conditions":565,"keywords":567,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":47},"100589990","NCT06961591","Cooking Skills to Improve Long-Term Weight Loss in Young Adults With Intellectual Disabilities","CHEF-ID","Inclusion Criteria:\n\n1. Diagnosis of mild-to-moderate intellectual disability (ID).\n2. 18-35 years of age.\n3. BMI \\>24.9, Body weight \\\u003C350lbs.\n4. Sufficient functional ability to understand directions, communicate preferences, e.g., foods, wants, and can communicate through spoken language e.g., request more to eat\u002Fdrink, asks for assistance with food preparation.\n5. Living at home with a parent\u002Fguardian, or in a supported living environment with a caregiver who assists with food shopping, meal planning, and meal preparation and agrees to serve as a study partner.\n6. Plan to attend all study required visits over the next 24 mos.\n\nExclusion Criteria:\n\n1. Unable to participate in PA.\n2. Insulin dependent diabetes as this condition requires medical monitoring beyond the scope of this study.\n3. Participation in a weight management program involving diet, PA, or pharmacotherapy in the past 6 mos.\n4. Diagnosis of Prader-Willi Syndrome.\n5. Pregnancy during the previous 6 mos., currently lactating or planned pregnancy in the following 24 mos. Participants who become pregnant will be removed from the study and referred to appropriate agencies for consultation.\n6. Serious medical risk, e.g., cancer, recent heart attack, stroke, angioplasty as determined by the PCP.\n7. Unwilling to be randomized.\n8. Unable to participate in small group, in-person instruction.\n9. Use of wheelchair or power chair as primary locomotion.",{"count":562,"type":22},114,[25],"The goal of this study is to see if adding hands-on cooking classes to a weight management program (called Chef-ID) helps young adults with intellectual disabilities lose more weight and keep it off compared to a standard weight loss program. The study will last 24 months and include three phases: 6 months of active support, 12 months of maintenance, and 6 months with no contact.\n\nThe investigators will look at how much weight participants lose over the first 18 months. Changes in cooking skills, body fat, health markers (like blood pressure and cholesterol), daily living skills, and caregiver stress will be tracked. Finally, factors that might help or prevent weight loss, and how changes in weight and body fat are linked to overall health will be explored.\n\nThis research will help inform on how to better support healthy lifestyles for people with intellectual disabilities.",[28,566],"Overweight and Obesity",[568,569,570,571],"Weight Loss Maintenance","Cooking Skills","Weight loss","Down syndrome","2025-10-03",{"date":574,"type":39},"2025-10-06",{"date":576,"type":39},"2025-05-19",{"date":578,"type":22},"2029-07-01",{"name":580,"class":98},"University of Kansas Medical Center",{"id":582,"slug":4,"hasResults":11,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":23,"phases":589,"briefSummary":590,"conditions":591,"keywords":593,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":604,"locationsCount":606},"100511152","NCT05935722","Evaluation of a Home-based Parenting Support Program: Parenting Young Children","Evaluation of a Home-based Parenting Support Program - Parenting Young Children - for Parents With Intellectual and Developmental Disabilities When There is a Risk for Neglect","PYC","Inclusion Criteria:\n\n* Parents with IDDs, including ID and other cognitive disabilities (e.g., ADHD and ASD).\n* Parents must have children aged 0-9 years living at home and be assessed by the social services to be eligible for tailored parenting support.\n\nExclusion Criteria:\n\n* Ongoing substance abuse, and\u002For mental illness of such nature and degree that it may affect parent management training.\n* Ongoing child abuse.",{"count":353,"type":22},[25],"Background: Parents with intellectual and developmental disabilities (IDDs) have a tendency to provide insufficient caregiving and often need parenting support to prevent neglect and child removal. However, parents with IDDs are not provided with appropriate support, and there is a lack of evidence-based programmes tailored to these parents' needs. Parenting Young Children (PYC) is a home-based parenting programme developed for parents with IDDs. PYC has shown promising clinical results in interview-based studies, but there is no evidence of its effectiveness. The purpose of the proposed study is to evaluate the PYC programme for improving parenting in parents with IDDs where there is risk of child neglect. The study will include a quantitative evaluation, a process evaluation, and a qualitative evaluation of the children's and parents' perspectives on participating in PYC.\n\nMethods: The quantitative evaluation will have a multi-centre, non-randomised, comparative study design. Eligible for participation are parents with IDDs who have children aged 0-9 years living at home and who are assessed as needing tailored parenting support. Thirty parents receiving PYC and thirty parents receiving treatment as usual (TAU) will be recruited from Swedish municipal social services. Outcome variables will be examined before and after the intervention, with a follow-up 6 months after completing the intervention. The primary outcome will be goal-attainment in parenting skills, and secondary outcomes will be parental self-efficacy and children's wellbeing. Interview methods will be used to explore the perspectives of parents and children in the PYC group.\n\nDiscussion: This study is motivated by the need for evidence-based support for parents with IDDs, and it focuses on upholding the centrality of child-caregiver relationships and family preservation, as well as children's rights and the rights of people with disabilities. Social services have expressed ethical concerns with employing a randomized design for this vulnerable group, and this study will therefore evaluate PYC in a non-randomized comparative study.",[28,592,384],"Attention Deficit Hyperactivity Disorder",[594,595,596,597],"Intellectual and developmental disabilities","parents","parenting skills","support programme","2025-08-11",{"date":600,"type":39},"2025-08-14",{"date":602,"type":39},"2022-09-08",{"date":54,"type":22},{"name":605,"class":98},"Örebro University, Sweden",5,{"id":608,"slug":4,"hasResults":11,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":612,"eligibilityCriteria":613,"healthyVolunteers":11,"sex":17,"minAge":138,"maxAge":614,"enrollmentInfo":615,"targetDuration":4,"studyType":23,"phases":617,"briefSummary":618,"conditions":619,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":626,"locationsCount":47},"100364450","NCT04025398","A Computer-based Cognitive Remediation Program for Adults With Intellectual Disability","REHABILITUS: a New Cognitive Remediation Tool for Adults With Intellectual Deficiency With Behavioral Disorders","REHABILITUS","Inclusion Criteria:\n\n* Adults aged 18 to 45 inclusive;\n* Behavioral disorders corresponding to a total score on the ABC scale \\> 15\n* Presence of a family caregiver (parent, friend) or professional (reeducator, professional of the medico-social sector) stakeholder of the project;\n* Diagnosis of mild to moderate intellectual disability (assessed by WAIS-IV battery and VABS-II less than 3 years ago;\n* French or secondary mother tongue;\n* Psychoactive treatment unchanged during the month prior to inclusion;\n* Adult or legal representative who has given written and informed consent to participate in the study. By default, the adult's oral agreement will be collected (as well as the written consent of the legal representative);\n* Affiliation to the social security scheme or beneficiary of such a scheme.\n\nExclusion Criteria:\n\n* Neurological disorders of vascular, infectious or neurodegenerative origin;\n* Taking medications for general medical purposes with a neurological or psychiatric impact (eg corticosteroids);\n* Simultaneous participation in any other cognitive remediation program targeting attentional, visuospatial and social cognition;\n* Refusal of participation of the person and\u002For his\u002Fher legal representative;\n* Not family or professional caregiver;\n* Presence of Autistic Spectrum Disorders (evaluated by ADOS and ADI if necessary according to the assessment of the investigator)","45 Years",{"count":616,"type":22},116,[25],"Adults with intellectual disabilities have great difficulty in adapting to social situations and relationships. Cognitive impairment associated with intellectual disability are important factors to understand their difficulties in processing social information. In the field of recognition of facial emotions in particular, basic cognitive processes such as visuospatial and attentional functions, are heavily involved. Cognitive remediation is a management tool widely used by practitioners to help patients who experience cognitive difficulties. Currently, no program can meet specific and validated the problems are adults with intellectual disabilities manner in their daily functioning",[28],"2025-07-30",{"date":622,"type":39},"2025-07-31",{"date":624,"type":39},"2020-06-17",{"date":504,"type":22},{"name":627,"class":98},"Hôpital le Vinatier",{"id":629,"slug":4,"hasResults":11,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":4,"eligibilityCriteria":633,"healthyVolunteers":11,"sex":17,"minAge":71,"maxAge":634,"enrollmentInfo":635,"targetDuration":4,"studyType":23,"phases":637,"briefSummary":638,"conditions":639,"keywords":640,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":649,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":655,"locationsCount":259},"100495982","NCT05738278","Heart Rate Informed Changes in Care for Non-Communicating Patients","Heart Rate Informed Changes in Care for Non-Communicating Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Between 5 and 70 years of age at the time of data collection\n* Autism spectrum disorder as evaluated by clinical psychologist\n* Communication difficulties\n* Living at a care home with round-the-clock staff for at least five days a week; or attending one-to-one staffed school\u002Fday-care at least five days a week.\n* Written informed consent is obtained from the subjects' legal representative.\n\nExclusion Criteria:\n\n\\- Having any autoimmune disorder or any type of cancer with ongoing chemotherapy.","70 Years",{"count":636,"type":22},38,[25],"The overarching aim is to generate knowledge to reduce incidence of pain in non-verbal patients' everyday life. The trial will 1) evaluate how HR can be used to identify potentially painful care procedures that should be re-evaluated in terms of the approach taken; 2) test the effect of heart rate (HR)-informed changes in potentially painful care procedures on biomarkers of pain, and 3) assess how six weeks of communication through HR affects the quality of communication between patient and caregiver.",[384,28,466],[641,642,28,643,644,274,645,646,647],"Heart Rate","Autistic Disorder","Social Interaction","Caregivers","Communication","Biomarkers","Pain","2025-07-01",{"date":650,"type":39},"2025-07-04",{"date":652,"type":39},"2023-02-27",{"date":654,"type":22},"2025-12-30",{"name":656,"class":98},"University of Oslo",{"id":658,"slug":4,"hasResults":11,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":4,"eligibilityCriteria":662,"healthyVolunteers":11,"sex":17,"minAge":71,"maxAge":663,"enrollmentInfo":664,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":665,"conditions":666,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":668,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":47},"100377804","NCT04199299","Sensors for Communication for Persons Who Cannot Communicate Unequivocally","The Use of Sensors to Improve Communication for Persons With Intellectual Disability Who Cannot Communicate Unequivocally","Inclusion Criteria:\n\n* intellectual disability with or without autism and\u002For cerebral palsy that render the participant unable to communicate his\u002Fher needs and reactions unequivocally.\n\nExclusion Criteria:\n\n* allergic skin reaction to chest strap","80 Years",{"count":170,"type":22},"Some persons with intellectual disability or comprehensive cerebral palsy cannot communicate unequivocally how they are, how they react to situations and people, whether they are in pain or experience discomfort, anger or fear. Their modes of communication (sounds, grimacing etc) may be unintelligible or ambiguous to their caregivers.\n\nWith the use of heart and\u002For respiration monitors the investigators aim to give these persons a means to communicate their immediate reactions or responses. The respiration monitor is meant to register sleep at night, so that the participants can communicate whether they have slept well or not the previous night.",[28,194,667],"Cerebral Palsy",{"date":650,"type":39},{"date":670,"type":39},"2020-02-01",{"date":672,"type":22},"2032-12-31",{"name":656,"class":98},{"id":675,"slug":4,"hasResults":11,"nctId":676,"briefTitle":677,"officialTitle":677,"acronym":4,"eligibilityCriteria":678,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":679,"targetDuration":4,"studyType":23,"phases":680,"briefSummary":681,"conditions":682,"keywords":4,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":684,"lastUpdatePostDateStruct":685,"startDateStruct":687,"completionDateStruct":689,"leadSponsor":691,"locationsCount":47},"100591008","NCT06974838","Explore the Therapeutic Effect of Theta Burst Stimulation on Emotion Regulation in Autism With Minimally Verbal Ability or Intellectual Disability","Inclusion Criteria:\n\n* Diagnosis of autism spectrum disorder, confirmed by DSM-5.\n* Individuals with minimal verbal ability or intellectual disability (FSIQ \\\u003C 70).\n\nExclusion Criteria:\n\n* Current or past severe neurological disorders, such as epilepsy, or significant visual or hearing impairments.\n* Current or past severe systemic diseases, such as cardiovascular disease, diabetes, or multiple sclerosis.\n* History of severe brain injury.\n* Presence of implanted metal devices, such as a pacemaker or medication pump.\n* Current or past severe psychiatric disorders, such as schizophrenia, bipolar disorder, or major depressive disorder.\n* Pregnancy.\n* Significant brain abnormalities, such as intracranial space-occupying lesions.\n* Family history of epilepsy.\n* History of febrile seizures.\n* Concurrent use of medications that increase the risk of seizures.\n* Sleep disorders during rTMS procedures.\n* Skin lesions or trauma at the stimulation site.\n* Deemed ineligible by the principal investigator (PI).\n* Participation in another clinical trial within the past month.\n* Suicidal ideation or suicide attempts within the past year.",{"count":353,"type":22},[25],"The investigator would like to investigate the impact of theta-burst stimulation over left DLPFC in autism with minimally verbal ability or intellectual disability",[384,683,28],"Minimally Verbal Ability","2025-05-14",{"date":686,"type":39},"2025-05-16",{"date":688,"type":22},"2025-05-26",{"date":690,"type":22},"2029-12-31",{"name":692,"class":98},"Chang Gung Memorial Hospital",""]